Greene, M. K., Chen, T., Robinson, E., Straubinger, N. L., Minx, C., Chan, D. K. W., . . . Scott, C. J. (2020). Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. Br J Cancer.
Citação norma ChicagoGreene, Michelle K., et al. "Controlled Coupling of an Ultrapotent Auristatin Warhead to Cetuximab Yields a Next-generation Antibody-drug Conjugate for EGFR-targeted Therapy of KRAS Mutant Pancreatic Cancer." Br J Cancer 2020.
Citação norma MLAGreene, Michelle K., et al. "Controlled Coupling of an Ultrapotent Auristatin Warhead to Cetuximab Yields a Next-generation Antibody-drug Conjugate for EGFR-targeted Therapy of KRAS Mutant Pancreatic Cancer." Br J Cancer 2020.